Publications by authors named "A Pares"
Article Synopsis
- The study looked at how patients with a liver disease called primary biliary cholangitis (PBC) respond to a treatment called ursodeoxycholic acid (UDCA).
- It found that many patients (33%) didn’t have a good response after one year, and those who lost their good response had a higher chance of needing a liver transplant or dying.
- The research showed that staying or getting back to a good response is important for improving long-term health.
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis.
Clin Gastroenterol Hepatol
December 2024
Article Synopsis
- The study investigates the prognostic value of changes in liver stiffness measurement (LSM) over time in patients with primary biliary cholangitis (PBC) who are being treated with ursodeoxycholic acid.
- It utilizes data from 3,078 patients over a 19-year period, finding that 59% of participants had an increase in LSM, which is linked to a higher risk of serious clinical events such as cirrhosis complications and liver transplants.
- The research concludes that monitoring LSM changes provides essential prognostic information, suggesting its potential as a valuable endpoint in clinical trials for PBC treatment.
Background & Aims: Recurrent primary biliary cholangitis (rPBC) develops in approximately 30% of patients and negatively impacts graft and overall patient survival after liver transplantation (LT). There is a lack of data regarding the response rate to ursodeoxycholic acid (UDCA) in rPBC. We evaluated a large, international, multi-center cohort to assess the performance of PBC scores in predicting the risk of graft and overall survival after LT in patients with rPBC.
View Article and Find Full Text PDFAdequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Hepatology
January 2024
Background And Aims: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended only when ALP levels remain above 1.5 times the upper limit of normal (×ULN) after 12-month UDCA.
View Article and Find Full Text PDF